


## PHARMACEUTICAL 2023



## CHINOOK THERAPEUTICS INC. Rank 141 of 446





## PHARMACEUTICAL 2023



## CHINOOK THERAPEUTICS INC. Rank 141 of 446

The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 31% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 118% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	385,592
Cost of Goods Sold	0
Intangible Assets	24,404
Liabilities, Current	50,835
Liabilities, Non-Current	34,494
Other Assets	147,180
Other Compr. Net Income	-3,109
Other Expenses	18,050
Other Liabilities	46,814
Other Net Income	1,559
Other Revenues	6,128
Property and Equipment	16,908
Research and Development	141,211
Selling, General and Administrative Expense	36,291

Output Variable	Value in 1000 USD
Assets	574,084
Liabilities	132,143
Expenses	195,552
Revenues	6,128
Stockholders Equity	441,941
Net Income	-187,865
Comprehensive Net Income	-189,420
Economic Capital Ratio	162%

